Stockreport

BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
PDF Data read-out expected in 1H 19 Results expected to support dose selection for anticipated registration trials in 2019 NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIR [Read more]